ACCURACY: A phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut): Results of 6-mg cohort Meeting Abstract
| Authors: | Ho, A. L.; Bowles, D. W.; Even, C.; Hao, D.; Kang, H.; Metcalf, R.; Muzaffar, J.; Oliva, M.; Perez, C. A.; Popovtzer, A.; Rodriguez, C. P.; Stemmer, S. M.; Van Herpen, C. M.; Winquist, E.; Wirth, L. J.; Worden, F. P.; Xia, B.; Gordon, G.; Gordon, G. B.; Ferrarotto, R. |
| Abstract Title: | ACCURACY: A phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut): Results of 6-mg cohort |
| Meeting Title: | ESMO Congress 2021 |
| Journal Title: | Annals of Oncology |
| Volume: | 32 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2021 Sep 16-21 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2021-09-01 |
| Start Page: | S803 |
| End Page: | S804 |
| Language: | English |
| ACCESSION: | WOS:000700527701367 |
| DOI: | 10.1016/j.annonc.2021.08.1314 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract #904P -- Source: Wos |
